Research Analysts Set Expectations for CAPR Q1 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities research analysts at B. Riley issued their Q1 2026 EPS estimates for Capricor Therapeutics in a report released on Sunday, September 14th. B. Riley analyst M. El-Saadi anticipates that the biotechnology company will earn ($0.40) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%.

Other equities analysts have also issued reports about the stock. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Roth Capital lowered their target price on shares of Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, July 14th. Jones Trading lowered their target price on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday, June 25th. Piper Sandler restated an “overweight” rating and set a $20.00 target price on shares of Capricor Therapeutics in a research report on Friday, July 11th. Finally, Oppenheimer lowered their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a research report on Monday, June 23rd. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $22.56.

Capricor Therapeutics Trading Down 2.3%

Shares of CAPR opened at $6.08 on Wednesday. The firm has a market cap of $277.98 million, a PE ratio of -3.71 and a beta of 0.73. The company’s 50 day simple moving average is $7.13 and its 200-day simple moving average is $9.67. Capricor Therapeutics has a 12-month low of $4.92 and a 12-month high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after acquiring an additional 61,701 shares during the period. Woodline Partners LP lifted its holdings in Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after acquiring an additional 99,384 shares during the period. Octagon Capital Advisors LP acquired a new stake in Capricor Therapeutics in the first quarter valued at $4,270,000. Goldman Sachs Group Inc. lifted its holdings in Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after acquiring an additional 116,373 shares during the period. Finally, Northern Trust Corp lifted its holdings in Capricor Therapeutics by 43.3% in the fourth quarter. Northern Trust Corp now owns 384,157 shares of the biotechnology company’s stock valued at $5,301,000 after acquiring an additional 116,086 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.